Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

3 Stocks to Buy for a Better Tomorrow
3 Stocks to Buy for a Better Tomorrow
You can do well while you're doing good. Some companies set out to make the world a better place, and they also happen to have solidly profitable business models. Owning their stocks lets you....
3 Stocks to Buy for a Better Tomorrow
3 Stocks to Buy for a Better Tomorrow
You can do well while you're doing good. Some companies set out to make the world a better place, and they also happen to have solidly profitable business models. Owning their stocks lets you....
3 Stocks to Buy for a Better Tomorrow
3 Stocks to Buy for a Better Tomorrow
You can do well while you're doing good. Some companies set out to make the world a better place, and they also happen to have solidly profitable business models. Owning their stocks lets you....
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
If you're one of the millions of Americans diagnosed with diabetes, large pharmacy benefits manager (PBM) Express Scripts (NASDAQ: ESRX) has good news for you. There's something you can do that....
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
This Simple Step Can Make Diabetes Patients Healthier -- and Possibly Wealthier
If you're one of the millions of Americans diagnosed with diabetes, large pharmacy benefits manager (PBM) Express Scripts (NASDAQ: ESRX) has good news for you. There's something you can do that....
Why Acorda Therapeutics Is Losing One-Quarter of Its Value Today
Why Acorda Therapeutics Is Losing One-Quarter of Its Value Today
After reporting that it has received a refuse-to-file letter from the FDA regarding its Parkinson's disease drug, Inbrija, shares in Acorda Therapeutics (NASDAQ: ACOR) are crashing 25% at 12:30....
Why Juno Therapeutics Stock Is Blasting Off Today
Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion....
Why Juno Therapeutics Stock Is Blasting Off Today
Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion....
Why Juno Therapeutics Stock Is Blasting Off Today
Why Juno Therapeutics Stock Is Blasting Off Today
Shares of Juno Therapeutics (NASDAQ: JUNO) are up by double digits for the second day in a row on extremely heavy volume. The catalyst behind this continued surge higher is the nearly $12 billion....
Why ImmunoGen, Inc. Jumped Higher Today
Why ImmunoGen, Inc. Jumped Higher Today
Shares of ImmunoGen (NASDAQ: IMGN) are up 17.5% at 12:50 p.m. EDT after the company announced an option deal with Jazz Pharmaceuticals (NASDAQ: JAZZ) for three antibody-drug conjugate (ADC) drugs....
Why Catalent Inc. Rose as Much as 17% This Morning
Why Catalent Inc. Rose as Much as 17% This Morning
Shares of drug-delivery technology specialist Catalent (NYSE: CTLT) jumped as much as 17% Tuesday morning in the wake of the company's 2017 fiscal year earnings report, released Monday after the....
Why Catalent Inc. Rose as Much as 17% This Morning
Why Catalent Inc. Rose as Much as 17% This Morning
Shares of drug-delivery technology specialist Catalent (NYSE: CTLT) jumped as much as 17% Tuesday morning in the wake of the company's 2017 fiscal year earnings report, released Monday after the....
These 3 Stocks Look Expensive but Are Actually Cheap
These 3 Stocks Look Expensive but Are Actually Cheap
A stock's price -- or even its current valuation -- rarely tell the whole story regarding its ability to produce respectable returns on capital over the long-term. In fact, deep value can be....
1 Little Known Healthcare Stock to Put on Your Radar
1 Little Known Healthcare Stock to Put on Your Radar
Alison Bauerlein's grandmother, Mae, was suffering from chronic obstructive pulmonary disease (COPD) at the turn of the century and was prescribed oxygen therapy. Thankfully, the therapy itself....
Is Inovio Pharmaceuticals Stock Poised for a Rebound?
Is Inovio Pharmaceuticals Stock Poised for a Rebound?
2017 was shaping up to be a good year for Inovio Pharmaceuticals (NASDAQ: INO). The stock was up more than 15% halfway through the year. And then shareholders got the bad news.In July, Inovio....
3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
There are fewer healthcare stocks with high yields than you might think. At least that's the case depending on your definition of "healthcare stocks" and "high yields." If you think a high-yield....
3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
3 Healthcare Stocks to Buy With Dividends Yielding More Than 3%
There are fewer healthcare stocks with high yields than you might think. At least that's the case depending on your definition of "healthcare stocks" and "high yields." If you think a high-yield....
Here's What Else Gilead Sciences Gets by Buying Kite Pharma
Here's What Else Gilead Sciences Gets by Buying Kite Pharma
Gilead Sciences' (NASDAQ: GILD) planned $11.9 billion acquisition of Kite Pharma (NASDAQ: KITE) nets it axi-cel, a CAR-T therapy that's already under FDA review. However, axi-cel isn't the only
Get Ready for More Acquisitions by Gilead Sciences
Get Ready for More Acquisitions by Gilead Sciences
Investors woke up Monday morning to a pleasant surprise from Gilead Sciences (NASDAQ: GILD). The big biotech announced plans to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion. The market....
Get Ready for More Acquisitions by Gilead Sciences
Get Ready for More Acquisitions by Gilead Sciences
Investors woke up Monday morning to a pleasant surprise from Gilead Sciences (NASDAQ: GILD). The big biotech announced plans to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion. The market....
Get Ready for More Acquisitions by Gilead Sciences
Get Ready for More Acquisitions by Gilead Sciences
Investors woke up Monday morning to a pleasant surprise from Gilead Sciences (NASDAQ: GILD). The big biotech announced plans to acquire Kite Pharma (NASDAQ: KITE) for $11.9 billion. The market....
We Got It Wrong With OPKO Health -- Now What?
We Got It Wrong With OPKO Health -- Now What?
In our "These Legendary CEO's Could Catch Lightning in a Bottle – Again" episode, Motley Fool Industry Focus: Healthcare contributor Todd Campbell picked OOKO Health (NASDAQ: OPK) as a stock to....
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Activity on the stock market was muted today as investors focused on the damage left by Hurricane Harvey. The major benchmarks showed mixed results, but stayed close to where they started the day.....
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Activity on the stock market was muted today as investors focused on the damage left by Hurricane Harvey. The major benchmarks showed mixed results, but stayed close to where they started the day.....
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Why Thor Industries, IXYS Corporation, and Kite Pharma Jumped Today
Activity on the stock market was muted today as investors focused on the damage left by Hurricane Harvey. The major benchmarks showed mixed results, but stayed close to where they started the day.....